Pharm'up development
ActiveSummary
Pharm'up development has been active since 2006 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €153k and a net result of €107k. Equity remains stable across the filed fiscal years (±1.1% per year). Its solvency ranks better than 59% of 11389 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.5% (very low).
Checked score
Score 2025
Axes · tick = 2024
Profitability100=
Solvency79▲+6
Growth78▲+20
Track record100
Bankruptcy probability, 12 months
0.5%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €12k at 30 days acceptable
Liquidity ample (current ratio 2.15 against 1.94 in 2024; short-term debt: 46.5% and cash: 56.8% of total assets), and 46.5% of the assets are financed with debt.
Credit check for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
53.5%
Return on assets
37.4%
Age of the figures
9 mo
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 46
Relative position
BE, all sectors
reference
Wholesale trade (NACE 46)
about 21% more bankruptcies
← fewer bankruptcies
more bankruptcies →
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025Equity per financial year
1819202122232425
2018 to 2025 · latest year €153k
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 01-07-2026, 30 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
30 d early
2024
30 d early
2023
28 d early
2022
26 d early
2021
10 d late
2020
32 d early
2019
42 d early
← before the deadline
after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
25-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Equity
€153k▲ 20.6%
2024 · €127k
Total assets
€287k▲ 9.1%
2024 · €263k
Net result
€107k▲ 6.8%
2024 · €100k
Working capital
€153k▲ 20.6%
2024 · €127k
Trend over the years
Click a name to add, emphasise or remove a line.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20212022202320242025
Operating result€99k▼ 31.9%€164k▲ 66.4%€130k▼ 20.6%€133k▲ 2.2%€157k▲ 18.1%
Net result€74k▼ 28.1%€122k▲ 65.3%€96k▼ 21.1%€100k▲ 4.4%€107k▲ 6.8%
Equity€143k▼ 4.2%€155k▲ 8.3%€105k▼ 32.2%€127k▲ 21.3%€153k▲ 20.6%
Total assets€246k▼ 11.9%€293k▲ 19.0%€291k▼ 0.7%€263k▼ 9.7%€287k▲ 9.1%
Debt€103k▼ 20.7%€138k▲ 33.9%€186k▲ 34.6%€136k▼ 27.1%€133k▼ 1.7%
Working capital€143k▼ 4.2%€155k▲ 8.3%€105k▼ 32.2%€127k▲ 21.3%€153k▲ 20.6%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
After the dip in 2023 the operating result has climbed two years in a row; 2025 is 18% above 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Equity and liabilities €287k
Equity
€153k ▲ 20.6%
Debt
€133k ▼ 1.7%
Debt's share of the balance-sheet total falls from 51.6% to 46.5%. Equity is higher and debt is lower.
Key figures and ratios
Current ratio
2.15▲
2024 · 1.94
Quick ratio
1.94▲
2024 · 1.70
Debt to equity
0.87▼
2024 · 1.06
ROE
69.9%▼
2024 · 78.9%
ROA
37.4%▼
2024 · 38.2%
Debt ≤ 1 year
€133k▼
2024 · €136k
Income taxes
€50k▲
2024 · €34k
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Other operating charges640/8 | €54 | €2k | - | - | - | - |
| Gross operating margin9900 | €99k | €166k | €130k | €133k | €157k | ▲ 18.1% |
| Operating profit (loss)9901 | €99k | €164k | €130k | €133k | €157k | ▲ 18.1% |
| Financial income75/76B | - | - | - | €2k | €504 | ▼ 72.3% |
| Recurring financial income75 | - | - | - | €2k | €504 | ▼ 72.3% |
| Financial charges65/66B | €346 | €348 | €370 | €348 | €383 | ▲ 10.2% |
| Recurring financial charges65 | €346 | €348 | €370 | €348 | €383 | ▲ 10.2% |
| Profit (loss) for the period before taxes9903 | €98k | €164k | €130k | €135k | €157k | ▲ 16.9% |
| Income taxes67/77 | €25k | €42k | €34k | €34k | €50k | ▲ 46.5% |
| Profit (loss) for the period9904 | €74k | €122k | €96k | €100k | €107k | ▲ 6.8% |
| Profit (loss) for the period to be appropriated9905 | €74k | €122k | €96k | €100k | €107k | ▲ 6.8% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €246k | €293k | €291k | €263k | €287k | ▲ 9.1% |
| Current assets29/58 | €246k | €293k | €291k | €263k | €287k | ▲ 9.1% |
| Stocks and contracts in progress3 | €38k | €26k | €27k | €33k | €29k | ▼ 12.4% |
| Stocks30/36 | €38k | €26k | €27k | €33k | €29k | ▼ 12.4% |
| Amounts receivable within one year40/41 | €83k | €93k | €89k | €48k | €95k | ▲ 96.2% |
| Trade receivables40 | €82k | €89k | €84k | €47k | €95k | ▲ 103% |
| Other amounts receivable41 | €2k | €3k | €6k | €2k | - | - |
| Current investments50/53 | - | - | - | €120k | - | - |
| Cash at bank and in hand54/58 | €125k | €174k | €175k | €61k | €163k | ▲ 165% |
| Deferred charges and accrued income490/1 | - | - | €114 | €47 | - | - |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €246k | €293k | €291k | €263k | €287k | ▲ 9.1% |
| Equity10/15 | €143k | €155k | €105k | €127k | €153k | ▲ 20.6% |
| Contributions10/11 | €10k | €10k | €10k | €10k | €10k | = |
| Reserves13 | €131k | €131k | €81k | €53k | €102k | ▲ 92.7% |
| Non-distributable reserves130/1 | €2k | €2k | - | - | - | - |
| Reserves not available under the articles1311 | €2k | €2k | - | - | - | - |
| Distributable reserves133 | €129k | €129k | €81k | €53k | €102k | ▲ 92.7% |
| Profit (loss) carried forward14 | €2k | €14k | €14k | €64k | €42k | ▼ 35.4% |
| Amounts payable17/49 | €103k | €138k | €186k | €136k | €133k | ▼ 1.7% |
| Amounts payable within one year42/48 | €103k | €138k | €186k | €136k | €133k | ▼ 1.7% |
| Trade debts44 | €15k | - | €647 | €399 | €3k | ▲ 727% |
| Suppliers440/4 | €15k | - | €647 | €399 | €3k | ▲ 727% |
| Taxes, remuneration and social security45 | €31k | €26k | €36k | €14k | €34k | ▲ 147% |
| Taxes450/3 | €31k | €26k | €36k | €14k | €34k | ▲ 147% |
| Other amounts payable47/48 | €57k | €112k | €150k | €121k | €96k | ▼ 20.9% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €74k | €122k | €96k | €100k | €107k | ▲ 6.8% |
| Operating cash flow (approximation) | €74k | €122k | €96k | €100k | €107k | ▲ 6.8% |
| Change in cash | - | €49k | €652 | €-113k | €102k | ▲ 189% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
01-07
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
31-12
Financial
Equity above €150kEq €153k ▲20.6%
8 profitable years in a row build equity to €153k.
01-07
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
03-07
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
05-07
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
31-12
Financial
Highest result since 2018net €122k ▲65.3%
Operating result €164k, net result €122k, both a record.
31-12
Financial
Equity above €150kEq €155k ▲8.3%
5 profitable years in a row build equity to €155k.
10-08
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema · 10 days late
2021
29-06
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
2020
19-06
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema
2019
31-12
Financial
Weakest financial yearnet €29k ▼48.1%
Net result drops to €29k, the lowest in the series; recovery starts the following year.
01-08
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema · 1 day late
2018
16-07
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema
2017
16-08
NBB filing
Annual accounts filed
fiscal year 2016 · micro schema · 16 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 2 acts read
About the unread acts
We know of 2 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Tournai · 1 establishment unit since 2006
Ground area
1,088 m²
Building footprint
132 m²
Volume, LiDAR
1,564 m³
2 parcels, Wallonia · tallest building 13.8 m, ±4 floors. Linked by address, not a title deed.
1 establishment unit
PHARM'UP DEVELOPMENT
since 20062.154.416.322
2 parcels
Wallonia
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 57462A0047/00A003 | Wallonia | 1,030 m² | 1 · 108 m² | 13.8 m · 4 fl. |
| 57462A0046/00W000 | Wallonia | 59 m² | 1 · 24 m² | 11.1 m · 3 fl. |
Linked by address, not proof of ownership
Good to know
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
PHARMACIE D'ANDENELLE
BE 0426.572.643
Andenne · Eq €153,459
LABOTICS
BE 0425.695.683
Antwerpen · Eq €153,693
MEDICAL TO MEDICAL EUROPE
BE 0474.085.718
Kaprijke · Eq €153,739
AB2
BE 0436.055.580
Etterbeek · Eq €154,122
EZI Biolab
BE 0500.516.337
Oupeye · Eq €152,455
Of 1,902 companies in sector 46460 we hold annual accounts for 1,116. 673 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded11-04-2006
Fiscal year end31-12
Activities, NACEBEL 2025
46460Wholesale of pharmaceutical and medical goods
46150Agents in the wholesale of furniture, household goods and hardware
82990Other business support services
Scores and ratios are computed by Checked and are not a credit decision.